Allarity Therapeutics Provides DRP®, Patent and Lab Update

What Happened
Allarity Therapeutics, Inc. announced on September 30, 2026 (filed via Form 8-K on October 1, 2026) an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, its patent portfolio and its in‑house laboratory capabilities. The company said these developments support the clinical development of its drug candidate stenoparib and expand potential external partnership opportunities. A press release dated September 30, 2026 was filed as Exhibit 99.1 to the 8-K.

Key Details

• Press release dated September 30, 2026; Form 8-K filed October 1, 2026.
• Updates focused on three areas: DRP® predictive technology, patent portfolio status, and in‑house lab capabilities.
• Company stated these advances support clinical development of stenoparib and may broaden external partnership opportunities.
• The announcement is informational; no financial results, material transactions, executive changes, or earnings details were reported in this filing.

Why It Matters
For investors, the update signals Allarity is strengthening its scientific and intellectual property foundations for stenoparib, which could make the program more attractive to partners or licensees and potentially reduce development risk. Because the filing does not include financial data or new agreements, it is an operational/strategic update rather than a change to earnings, management, or corporate structure. Monitor future announcements for clinical data, patent grants, or partnership deals that might have direct financial impact.